Histone deacetylases inhibitors (HDACi) include a growing number of drugs that share the
ability to inhibit the enzymatic activity of some or all the HDACs. Experimental and preclinical …

Histone deacetylases (HDACs) are enzymes that regulate the deacetylation of numerous
histone and non-histone proteins, thereby affecting a wide range of cellular processes …

Duchenne muscular dystrophy (DMD) is a life-threatening genetic disease that currently has
no available cure. A number of pharmacological strategies that aim to target events …

Pharmacological treatment of Duchenne muscular dystrophy (DMD) with histone
deacetylase inhibitors (HDACi) is currently being tested in clinical trials; however, pre …

The dynamics of gene expression are regulated by histone acetylases (HATs) and histone
deacetylases (HDACs) that control the acetylation state of lysine side chains of the histone …

The overlapping histological and biochemical features underlying the beneficial effect of
deacetylase inhibitors and NO donors in dystrophic muscles suggest an unanticipated …

We propose that the decline in anabolic signals ('passive atrophy') and activation of
catabolic pathways ('active atrophy') contribute differently to the pathogenesis of muscle …

Skeletal muscle is a highly adaptive organ that sustains continuous metabolic changes in
response to different functional demands. Healthy skeletal muscle can adjust fuel utilization …

Duchenne muscular dystrophy (DMD) causes progressive skeletal muscle degeneration
and currently there are few therapeutic options. The identification of new drug targets and …

Abstract Background Histone deacetylase 4 (HDAC4) is a stress‐responsive factor that
mediates multiple cellular responses. As a member of class IIa HDACs, HDAC4 shuttles …